Data Summary {#s2}
============

**1**. All raw *[Mycobacterium tuberculosis](http://doi.org/10.1601/nm.10886)* sequence data are available from the European Nucleotide Archive (ENA) short-read archive (project ID ERP000436 and ERP001072).

**2**. *[M. tuberculosis](http://doi.org/10.1601/nm.10886)* strain H37Rv is available from GenBank; accession number NC_000962.3.

###### Impact Statement

Tuberculosis (TB), caused by *[Mycobacterium tuberculosis](http://doi.org/10.1601/nm.10886)*, remains a major global health concern, responsible for around 1.64 million deaths globally in 2017, with a greater disease burden in high-incidence regions. Studies detailing the epidemiological and genetic factors influencing TB transmission are complicated by the difficulty of accurately resolving accurate transmission due to a variable latency period in which within-host evolution can occur and low mutation rate. Our work reconstructs transmission networks in *[M. tuberculosis](http://doi.org/10.1601/nm.10886)* cases collected as part of a large-scale, long-term study in a high-burden region of northern Malawi, applying a sophisticated Bayesian approach that incorporates parameters for incomplete sampling of the population and within-host pathogen evolution to identify risk factors associated with recent transmission and onward infection. Our approach is of high interest to those using genomics in clinical and research settings, in particular to the tuberculosis research and clinical communities and those investigating outbreaks and pathogen transmission, where the methodological pipeline described in our study can be applied in different settings. In addition, the risk factors and genomic variants found to be associated with transmissibility in *[M. tuberculosis](http://doi.org/10.1601/nm.10886)* can inform further work on tuberculosis transmission and management for the spread of infection.

Introduction {#s3}
============

Establishing patterns of transmission -- who infected whom -- for infectious pathogens is critical for controlling outbreaks and informing health management strategies to prevent the spread of infection. Tuberculosis (TB), caused by *Mycobacterium tuberculosis (Mtb*), remains a major global health concern, responsible for 1.6 million deaths in 2017 alone, including nearly 400 000 deaths attributed to HIV-associated infection \[[@R1]\]. Despite initiatives aimed at reducing global incidence rates, such as the World Health Organization's 'End TB Strategy' \[[@R1]\], many regions are falling behind set targets for case reduction. Understanding and preventing transmission is fundamental to disease control, but the accurate characterization of networks is difficult, especially as the onset of active disease follows a long and highly variable latency period during which within-host evolution can occur \[[@R2]\]. There is a paucity of long-term studies in high-incidence areas \[[@R4]\] to assist with providing much needed biological and epidemiological insights into transmission.

The Karonga Prevention Study (now Malawi Epidemiology and Intervention Research Unit, MEIRU) is based in Karonga District in northern Malawi, which has a population of over 300 000, a high TB incidence (\~100 cases per 100 000 population) and an HIV prevalence of around 10 % \[[@R6]\]. Since the 1980s, it has been conducting research on TB in the area, collecting sputum specimens from individuals presenting at the district hospital and peripheral health centres with suspected TB \[[@R9]\]. More than 2100 *Mtb* DNA samples from the mid-1990s onwards, encompassing strains of the major lineages 1--4 \[[@R6]\], have undergone whole-genome sequencing (WGS). These genomic data are supported by in-depth demographic data, including age, sex, previous disease history and HIV status. The combined dataset presents a unique opportunity to investigate evolutionary relationships among TB patients in a high-incidence area over an extended study period (nearly 20 years). The samples collected between 1995--2010 have previously been used to assess transmission using a simple disease outbreak model, allowing up to 10 single-nucleotide polymorphism (SNP) differences between cases \[[@R6]\]. This simple thresholding approach revealed decreases in transmission over time and with age, as well as lineage differences in transmission \[highest in lineage 2 (East Asian, including Beijing) and lowest in lineage 1 (Indo-Oceanic)\] \[[@R6]\].

Using an SNP threshold for establishing transmission links is suitable for confirming the absence of transmission between distant strains, but can be over-simplistic for determining the timing and direction of actual transmission events in evolving populations \[[@R14]\]. Different thresholds have been applied previously across *Mtb* transmission studies \[[@R15]\], and the amount of genomic variation in strains can be influenced by the culturing protocol and bioinformatics pipeline used to call SNPs, making a consensus difficult. Most importantly, it does not explicitly allow for missing links in transmission chains.

This study investigated *Mtb* transmission dynamics in a high-TB-burden setting using advanced computational techniques. We applied probabilistic modelling to infer high-likelihood transmission events in 1857 TB cases from Karonga between 1995 and 2014. Specifically, the TransPhylo software package \[[@R3]\] was employed to provide Bayesian model-based inference of transmission reconstruction across a time-calibrated phylogenetic input, allowing for within-host diversity and incomplete sampling to infer the likelihood and time of transmission events. By accurately constructing transmission networks, we aimed to identify demographic factors that are associated with: (i) recent transmission; (ii) large, persisting transmission clusters; and (iii) transmissibility. We also applied phylogenetic convergence testing (phyC) and genome-wide association (GWAS) to detect pathogen genetic variants that were associated with a transmissible phenotype.

Methods {#s4}
=======

Sample collection and preparation {#s4-1}
---------------------------------

In Karonga District, patients exhibiting symptoms of TB were reviewed by project staff at the district hospital and local health centres, with those diagnosed with the disease interviewed to obtain further details. The information collected included: sex, age and contact with prior TB cases. Patients were HIV-tested after counselling and, if consent was given, a minimum of three sputum samples were taken from each patient. Further details of the study design are available elsewhere \[[@R8]\]. The study was approved by the National Health Sciences Research Committee in Malawi and by the London School of Hygiene and Tropical Medicine ethics committee. Informed consent was obtained for all participants.

Sequencing and variant calling {#s4-2}
------------------------------

WGS was carried out on \>2000 *Mtb* isolates from Karonga (European Nucleotide Archive at EMBL-EBI, study numbers ERP000436 and ERP001072). DNA was extracted from a sweep of multiple colonies from solid cultures and sequenced using the Illumina HiSeq 2000 platform, generating 100 bp paired-end reads. Additional culture and sequencing information has been provided elsewhere \[[@R6]\]. Quality checking of sequenced reads was carried out using FastQC software, with adapter sequences and low-quality reads removed using the Trimmomatic program. Reads were mapped to the *Mtb* H37Rv reference strain (GenBank no.: NC_000962.3) with BWA-mem software \[[@R19]\] and SNP and small insertion and deletion (INDEL) variants were called using the Samtools suite \[[@R20]\]. Low-quality variants (phred score Q\<20, read depth DP\<5) and SNPs found in repeat regions were excluded \[[@R21]\]. Variants were removed if there was a missing call (either through non-alignment of reads or low coverage) in \>10 % of samples. Where there were multiple, longitudinal samples taken from a patient during the same disease episode of disease, the earliest collected sample was used. Samples with a high likelihood of mixed infection (two or more concurrent *Mtb* strains) were identified \[[@R12]\] and removed from further analysis. In the remaining 1857 samples, heterozygous sites were called as the majority allele if there was at least 75 % consensus across reads, with a minimum coverage of 20-fold; otherwise they were called as missing. Additionally, *de novo* assembly of isolates was carried out with VelvetOptimiser \[[@R22]\], a wrapper script that optimizes parameters for the Velvet assembler software \[[@R23]\] . Genomes were annotated using Prokka \[[@R24]\] and Roary \[[@R25]\].

Phylogenetic analysis {#s4-3}
---------------------

Initially, broad putative clusters of cases were constructed for application of the Bayesian transmission inference analysis. The clusters were constructed using R software to group cases with a maximum pairwise SNP distance threshold of 50 SNPs, i.e. a case was included in a cluster if there were ≤50 SNP differences from one or more cases within this cluster. The threshold to determine potential transmission links between patients has previously typically been fixed between 5 and 12 SNP differences \[[@R6]\], although recent analysis of within-patient variation has suggested this estimate may be too low \[[@R27]\]. We chose to define broad initial clusters for further analysis to allow for missing cases and potential transmission between more genetically distant cases.

Phylogenetic trees were assembled for each transmission cluster with [beast]{.smallcaps} v1.8 \[[@R28]\] using SNP data (excluding highly variable *PE/PPE* and known antimicrobial resistance associated genes, and INDELs) and calibrated by episode start dates (earliest of specimen collection or registration) at the tips. Prior parameters were optimized for each cluster tree by performing preliminary analyses with 5×10^7^ Markov chain Monte Carlo (MCMC) iterations to determine the substitution model \[Hasegawa, Kishino and Yano (HKY) Gamma; generalized time-reversible (GTR) Gamma\]; the molecular clock (strict; uncorrelated relaxed); and the population size and growth (constant; exponential; extended Bayesian skyline plot). The performance of each prior parameter iteration was assessed through the comparison of posterior marginal likelihood estimates and checked for convergence using traces of effective sample size (ESS) distributions in Tracer v1.8 software. Three final runs of 10^8^ MCMC iterations using the best fitting prior parameters were combined using LogCombiner v1.8, discarding a 10 % burn-in for each run, to reach posterior ESS distributions above 200 for each parameter. Final maximum clade credibility trees summarizing the posterior sample of trees in the combined MCMC runs were produced using TreeAnnotator v.1.8 software. Additionally, population-level and lineage-specific maximum-likelihood (ML) phylogenies were constructed with RAxML \[[@R29]\] using the GTR+GAMMA substitution model and 1000 bootstrap replicates.

Inferring transmission events {#s4-4}
-----------------------------

We used the R software package TransPhylo \[[@R3]\] to reconstruct transmission within our clusters, allowing for unsampled cases and within-host diversity. The program employs a stochastic branching process algorithm using the tip-calibrated phylogenetic trees as input \[[@R28]\], incorporating information such as branch lengths and substitution rates. The algorithm requires the user to define model priors estimated from characteristics of the pathogen and sample population, such as generation time and sampling density, which we tested through a sensitivity analysis on two large clusters representing lineage 2 (*n*=27) and lineage 3 (*n*=37) strains. The results of the sensitivity analysis and more detailed explanations of the rationale behind these prior parameter choices are specified in Supplementary Material S2.

The generation time is defined as the time between a host becoming infected and infecting another individual, modelled as a gamma distribution. This parameter is particularly important to define for pathogens with potentially long, variable periods of latency, such as *Mtb*, where the time between a host becoming infected and infecting others can range from a few weeks to many years \[[@R2]\]. Due to this highly variable latent and infectious period in *Mtb* infections, we set a wide generation time gamma distribution with a median of 3.9 years and a long tail (gamma shape=2.2, scale=2.1, rate=0.48).

Prior values for the sampling interval (the time between the onset of infection and the sample collection date, modelled with a gamma distribution), sampling density (*π*), basic reproductive number (*R*) and within-host effective population size (*N* ~eg~ *),* were also specified to refine the biological relevance of the model. The sampling interval prior distribution was chosen to be the same as the generation time (median of \~3.9 years; gamma shape=2.3, scale=2.1) as the time from diagnosis to end of infectiousness is short compared to the latent period (Supplementary Material S2). We set *R=*1.75 \[estimated from the sensitivity analysis (Supplementary Material S2)\] and *N* ~eg~=1.48 (based on a previous study \[[@R14]\]), with these two values being updated through MCMC iterations. Finally, we chose to test a fixed sampling density of *π*=0.5 based on the results of sensitivity analysis and allowing for unsampled cases through the unavailability of WGS data or undiagnosed cases.

The algorithm was applied to each cluster for 5×10^5^ MCMC iterations, sampling every 10 000 states, with a 10 % burn-in, and convergence-tested through inspection of trace plots of effective sample size (ESS). Transmission links with a posterior probability of more than 0.5 were accepted and the direction was inferred by using the highest probability where links in both directions were accepted. Where more than one potential infector case was inferred for the same recipient, the transmission link with the highest probability was taken. We accounted for the evidence that transmission from patients with extrapulmonary TB is highly unlikely \[[@R30]\] by excluding these links. Manual inspection of small INDEL profiles between linked cases and tracing of epidemiological links between cases (where available) were used to confirm transmission links and the direction of transmission.

Transmission networks and demographic associations {#s4-5}
--------------------------------------------------

We characterized the final set of transmission networks as including cases either directly linked or with up to two unsampled hosts between the transmission events inferred through the TransPhylo analysis. The host demographic and epidemiological metadata collected with each case were analysed for significant associations with recent infection (transmission within previous 3 years, first 3 years of data collection excluded), large clusters (≥10 sampled cases and ≥1 case per year) and transmissibility (cases transmitting to a recipient within 4 years versus single cases, last 4 years of data collection excluded), through logistic regression. These metadata included major lineage, age, sex, collection date, HIV status, treatment outcome, birthplace, recent residence, and isoniazid and rifampicin resistance.

Genomic variant analysis {#s4-6}
------------------------

SNPs associated with transmissibility were identified by applying phyC, a test for detecting shared variants among groups through evolutionary convergence \[[@R31]\], comparing infector TB cases (cases transmitting to a recipient within 4 years) against the cases not found in a transmission cluster. We tested for sites that were associated with transmissibility in separate lineages and across the whole population. The likelihood of association was established by significance testing with Fisher's exact test (*P*\<0.05 \[[@R31]\]). A complementary mixed model GWAS approach \[[@R32]\] was also conducted to reveal any SNPs or loci highly associated with transmitting cases, including an analysis of aggregated numbers of non-synonymous mutations per gene. A significance threshold of *P*\<10^−5^ was assigned by applying a Bonferroni correction for multiple testing. All analyses were performed in *R* and Python.

Results {#s5}
=======

*Mtb* lineages {#s5-1}
--------------

High-quality WGS data were available for 2129 *Mtb* genomes collected between 1995 and 2014. Multiple samples from the same individual during the same disease episode or through likely relapse \[[@R11]\] (*n*=77) or with a high likelihood of mixed infection (*n*=195) \[[@R12]\] were removed from further analysis, resulting in 1857 isolates being used in our analysis. The majority of isolates belonged to major lineage 4 (1279 isolates; 68.7 %), followed by lineages 1 (*n*=290; 15.6 %), 3 (*n*=217; 11.6 %) and 2 (*n*=71; 3.8 %) ([Fig. 1a](#F1){ref-type="fig"}), with their proportions changing through the study period, but lineage 4 strains always being predominant ([Fig. 1b](#F1){ref-type="fig"}). There were differences in diversity among strains of different major lineages, with lineages 2 and 3 being characterized by the least pairwise diversity \[median=82 SNPs (interquartile range, IQR, 59--128) and 130 SNPs (IQR 21--137), respectively\], followed by lineage 4 \[median=198 SNPs (IQR 94--339)\] and lineage 1 with the highest diversity between isolates \[median=424 SNPs (IQR 167--491)\] ([Fig. 2a](#F2){ref-type="fig"}).

![(a) Pairwise SNP distance by lineage between all Karonga strains used in the study. (b) Transmission cluster size by lineage, excluding non-clustered individuals. Clusters are defined as sampled strains (excluding non-sampled cases) linked either through direct transmission or with up to two transmission events inferred between individuals. *P*-values are a comparison against lineage 4 using the Wilcoxon rank sum test. (c) Median SNP distance in transmission clusters (sampled cases only). *P*-values are a comparison against lineage 4 using the Wilcoxon rank sum test. (d) Pairwise SNP distance between individuals in direct transmission events. *P*-values are a comparison against lineage 4 using the Wilcoxon rank sum test.](mgen-6-361-g001){#F2}

![(a) Maximum-likelihood phylogenetic tree of the 1857 Karonga strains used in this study, showing lineages clustering into monophyletic groups. Lineage 1 is shown in blue, lineage 2 in red, lineage 3 in green and lineage 4 in orange. (b) The total number of sequenced cases and the proportion of strains collected, by lineage, over the study period 1995--2014 in 4-year categories.](mgen-6-361-g002){#F1}

Transmission networks {#s5-2}
---------------------

We found that 1355 isolates (73.0 %) were clustered into 281 transmission networks (or 57.8 % of isolates using the n-1 method removing the index case \[[@R33]\]) after removing likely relapse cases as previously described \[[@R11]\]. [Fig. 3](#F3){ref-type="fig"} shows an example of an inferred transmission network. Lineage 2 strains had the highest clustering rate (69/71 strains; 97.2 %), followed by lineage 3 (178/217 strains; 82.0 %), lineage 4 (911/1279; 71.2 %) and lineage 1 (197/290; 67.9 %). Cluster sizes ranged from 2 to 51 samples (median 3 cases, IQR 2--5) and were largest for lineage 2 strains (median 4 cases, IQR 4--12) ([Fig. 2b](#F2){ref-type="fig"}). Strains belonging to lineage 1 were found in the smallest clusters (median 3 cases, IQR 2--4) with the highest genetic diversity (3.75 SNPs; IQR 1--5) ([Fig. 2c](#F2){ref-type="fig"}). Lineage 4 had the lowest genetic diversity within clusters (median 2 SNPs, IQR 1--3.25), although this was not significantly different from lineage 2 and 3 clusters (Wilcoxon *P*=0.15 and 0.54, respectively) and was likely due to the significantly smaller average cluster size (Wilcoxon *P*\<0.01).

![An example transmission network of lineage 2 strains reconstructed with TransPhylo software. Sampled cases are illustrated by filled dots and non-sampled, inferred intermediate hosts are indicated with unfilled dots. The direction of transmission is from left to right with the transmission date on the *x*-axis.](mgen-6-361-g003){#F3}

We identified 544 direct transmission events between sampled cases (i.e. with no inferred unsampled host in-between), as detailed in the Supplementary Material S1. The time between direct transmission events ranged from 41 days to 12.4 years, with a median of 1.7 years (IQR 0.9--3.2 years). The median SNP difference between cases inferred to be linked by a direct transmission event was relatively low, with a median of 0 SNPs (IQR 0--1), and this was consistent between direct transmissions in different lineage clusters ([Fig. 2d](#F2){ref-type="fig"}). The number of SNP differences between directly linked cases ranged from 0 to 12 SNPs, although the majority of cases differed by fewer than 5 SNPs (99.1 %). We also found no INDEL differences between directly linked cases.

Recent infection {#s5-3}
----------------

Recent infection was defined as transmission links for which the source case was within 3 years of the recipient, estimated by TransPhylo. Cases occurring before 1999 were excluded to ensure that the prior 3 years of data were available. We found that 49.4 % of cases showed evidence of recent infection ([Table 1](#T1){ref-type="table"}), with lineage 2 cases having the highest proportion (71.9 %) and lineage 1 (39.6 %) the lowest. We also found significant associations with age, with a higher proportion of recent infection in the younger age groups but no significant reduction in the proportion of recent infection over time.

###### 

Demographic characteristics associated with recent infection, defined as cases for whom the source of infection has been inferred within the last 3 years. Cases prior to 1999 are excluded. Odds ratios and *P*-values are calculated through logistic regression and Wald chi-Squared test, adjusted for age, sex, year and lineage

                              Recent infection/total   \% recent infection   Odds ratio (95 % CI)   *P*-value
  --------------------------- ------------------------ --------------------- ---------------------- -----------
  **Year**                                                                                          
    1999--2001                181/367                  49.3                  1                      
    2002--2004                171/379                  45.1                  0.9 (0.6--1.2)         
    2005--2007                137/298                  46.0                  0.9 (0.7--1.2)         
    2008--2010                93/219                   42.5                  0.8 (0.5--1.1)         
    2011--2014                108/219                  49.3                  1.0 (0.7--1.4)         0.52
  **Lineage**                                                                                       
    1                         86/232                   37.1                  0.7 (0.5--0.9)         
    2                         46/64                    71.9                  2.8 (1.7--5.1)         
    3                         88/187                   47.1                  1.0 (0.7--1.4)         
    4                         470/999                  47.0                  1                      \<0.01
  **Age group (years**)                                                                             
    \<20                      33/64                    51.6                  1.8 (1.0--3.1)         
    20--29                    204/370                  55.1                  2.1 (1.5--2.9)         
    30--39                    236/528                  44.7                  1.4 (1.0--1.9)         
    40--49                    132/290                  45.5                  1.4 (1.0--2.0)         
    50+                       85/230                   37.0                  1                      \<0.01
  **Sex**                                                                                           
    Female                    361/752                  48.0                  1                      
    Male                      329/730                  45.1                  0.9 (0.7--1.1)         0.33
  **HIV status**                                                                                    
    Negative                  235/514                  45.7                  1                      
    Positive on ART           64/123                   52.0                  1.3 (0.8--1.9)         
    Positive no ART           274/584                  46.9                  1.1 (0.8--1.3)         0.51
  **Previous TB**                                                                                   
    Yes                       101/167                  60.5                  1.9 (1.4--2.6)         
    No                        589/1315                 44.8                  1                      \<0.01
  **TB type**                                                                                       
    Smear positive            540/1144                 47.2                  1                      
    Smear negative            135/294                  45.9                  0.9 (0.7--1.2)         
    Extrapulmonary            15/44                    34.1                  0.5 (0.3--1.0)         0.09
  **Outcome**                                                                                       
    Completed                 485/1023                 47.4                  1                      
    Died                      144/286                  50.3                  1.1 (0.9--1.5)         
    Lost/transferred          55/149                   36.9                  0.6 (0.4--0.9)         0.02
  **Isoniazid Resistance**                                                                          
    Resistant                 59/99                    59.6                  1.8 (1.2--2.7)         
    Sensitive                 609/1313                 46.4                  1                      \<0.01
  **Rifampicin resistance**                                                                         
    Resistant                 5/12                     41.7                  0.7 (0.2--2.2)         
    Sensitive                 664/1399                 47.5                  1                      0.65
  **Recent Residence**                                                                              
    Karonga                   571/1158                 49.3                  1                      
    Other Malawi              84/228                   36.8                  0.6 (0.4--0.8)         
    Other country             21/66                    31.8                  0.5 (0.3--0.8)         \<0.01
  **Birthplace**                                                                                    
    Karonga                   453/906                  50.0                  1                      
    Other Malawi              121/300                  40.3                  0.7 (0.5--0.9)         
    Other country             102/252                  40.5                  0.7 (0.5--0.9)         \<0.01

ART, antiretroviral therapy.

The risk of recent infection was higher in patients who had had a previous episode of TB \[odds ratio adjusted for age, sex, year and lineage (aOR)=2.0 (95 % CI: 1.4--2.9; *P*\<0.01)\] compared to no previous episode. Recent infection was also lower in patients from outside Karonga district (though this may be due to sampling bias as the source of infection is less likely to be captured as it may be outside the sample population), and higher in patients with isoniazid-resistant *Mtb* \[aOR=1.6 (95 % CI 1.0--2.5; *P*=0.01)\]. There was also some evidence of a lower proportion of recent infection in extrapulmonary TB cases \[aOR=0.5 (95 % CI 0.3--1.0; *P*=0.06\] compared to smear-positive cases and in patients who were subsequently lost or transferred versus those completing treatment or who died.

By increasing the number of years from 3 to 5 to characterize recent infection, all associated factors identified with recent infection at 3 years were also found (Supplementary Material S2, Table S1). In addition, we found that HIV-positive patients were more likely to have recent infection than HIV-negative patients.

Large clusters {#s5-4}
--------------

Cases within large, persistent transmission clusters (\>10 cases and a rate of \>1 case per year, [Fig. 4](#F4){ref-type="fig"}) were compared to small clusters (\<5 cases) and unclustered cases. This resulted in 23 large clusters of between 10 and 51 cases. Intermediate-sized clusters (\>10 cases but \<1 case per year, or between 5 and 10 cases) were excluded from this analysis to allow for a more distinct comparison. Clusters with the earliest collection date after 2010 were also excluded as these may have the potential to continue growing into larger clusters after the study period.

![Cluster size by the number of cases per year (calculated as the date range of a cluster divided by the number of cases) in clusters with ≥five cases. Large clusters are defined as clusters of ≥10 cases and \>1 case per year (red dashed lines), and are shown in the upper right quadrant of the figure.](mgen-6-361-g004){#F4}

Lineage 2 strains were significantly more likely to be found in large clusters \[aOR=3.4 (95 % CI 1.9--6.3)\], compared to lineage 4. The oldest patients (50+ years) were least likely to have large cluster strains. Residence within Karonga district was associated with large cluster strains, though again this is likely due to sampling bias, as cases within a cluster from outside the Karonga district would not be captured within our sample population. Additionally, there was some evidence that HIV-negative patients and those with rifampicin-resistant *Mtb* strains were less likely to be in large clusters ([Table 2](#T2){ref-type="table"}).

###### 

Demographic characteristics associated with large clusters (cases in clusters of ≥10 cases and \>1 case per year). Cases in clusters ≥10 cases but \<1 case per year, and cases in clusters with the index case after 2010, are excluded. Odds ratios are calculated through logistic regression and *P*-values by the Wald chi-squared test, adjusted for age, sex, year and lineage

                              Large clusters/total   \% large clusters   Odds ratio (95 % CI)   *P*-value
  --------------------------- ---------------------- ------------------- ---------------------- -----------
  **Year**                                                                                      
    1995--1998                81/304                 26.6                1                      
    1999--2001                80/302                 26.5                1.0 (0.7--1.4)         
    2002--2004                95/303                 31.4                1.2 (0.9--1.8)         
    2005--2007                82/247                 33.2                1.4 (0.9--2.0)         
    2008--2010                57/184                 31.0                1.2 (0.8--1.8)         
    2011--2014                52/188                 27.7                1.0 (0.7--1.5)         0.39
  **Lineage**                                                                                   
    1                         69/257                 26.8                0.9 (0.7--1.3)         
    2                         27/47                  57.4                3.4 (1.9--6.3)         
    3                         59/176                 33.5                1.3 (0.9--1.8)         
    4                         292/1048               27.9                1                      \<0.01
  **Age group (years**)                                                                         
    \<20                      23/68                  33.8                1.9 (1.0--3.4)         
    20--29                    130/403                32.6                1.8 (1.2--2.6)         
    30--39                    155/527                29.4                1.5 (1.1--2.2)         
    40--49                    89/299                 29.8                1.5 (1.0--2.3)         
    50+                       50/231                 21.6                1                      0.05
  **Sex**                                                                                       
    Female                    220/761                28.9                1                      
    Male                      227/767                29.6                1.0 (0.8--1.3)         0.80
  **HIV status**                                                                                
    Negative                  131/503                26.0                1                      
    Positive on ART           40/108                 37.0                1.6 (1.0--2.6)         
    Positive no ART           187/583                32.1                1.3 (1.0--1.8)         0.08
  **Previous TB**                                                                               
    Yes                       55/148                 37.2                1.5 (1.0--2.1)         
    No                        392/1380               28.4                1                      0.12
  **TB type**                                                                                   
    Smear-positive            254/818                31.1                1                      
    Smear-negative            79/294                 26.9                0.9 (0.6--1.1)         
    Extrapulmonary            37/163                 22.7                0.8 (0.4--1.3)         0.38
  **Outcome**                                                                                   
    Completed                 307/1003               30.6                1                      
    Died                      96/315                 30.5                1.0 (0.8--1.3)         
    Lost/transferred          43/190                 22.6                0.7 (0.5--1.0)         0.11
  **Isoniazid resistance**                                                                      
    Resistant                 24/99                  24.2                0.7 (1.0--1.2)         
    Sensitive                 408/1366               29.9                1                      0.20
  **Rifampicin resistance**                                                                     
    Resistant                 1/15                   6.7                 0.2 (0.0--0.9)         
    Sensitive                 432/1451               29.8                1                      0.09
  **Recent residence**                                                                          
    Karonga                   360/1114               32.3                1                      
    Other Malawi              51/248                 20.6                0.5 (0.4--0.8)         
    Other country             16/89                  18.0                0.5 (0.3--0.8)         \<0.01
  **Birthplace**                                                                                
    Karonga                   281/907                31.0                1                      
    Other Malawi              85/315                 27.0                0.8 (0.5--1.1)         
    Other country             69/264                 26.1                0.8 (0.6--1.1)         0.21

ART, antiretroviral therapy.

Transmissibility {#s5-5}
----------------

Infectors were defined as cases that were inferred to have transmitted *Mtb* to either sampled or unsampled cases. Demographic factors associated with these cases were compared to those with no onward transmission. Extrapulmonary cases, and those seen after 2010, which may transmit after the study period, were excluded. Four hundred and sixty-eight out of 1556 (30.1 %) cases seen before 2011 transmitted *Mtb* to at least 1 person; and 369 (23.7 %) transmitted with a serial interval of 4 years or less. Most infectors that transmitted within 4 years were responsible for a single onward transmission (80.2 %), with the number of secondary cases caused by infectors ranging from 1 to 6.

[Table 3](#T3){ref-type="table"} shows the demographic associations with transmission to another case within 4 years, applying ordered logistic regression in relation to the number of secondary cases caused by each infector. There were lineage differences associated with transmissibility, with lineage 2 strains the most likely to transmit and those from lineage 1 the least likely. The proportion of infector cases in the total population decreased significantly per year throughout the duration of the study period (*P*\<0.05) (Supplementary Material S2, Fig. S1). Patients under 50 years of age and those with smear-positive disease were more likely to transmit. Patients who died or were transferred/lost to follow-up, those with isoniazid resistance and those born outside Karonga District were less likely to transmit. Associations were similar when comparing all transmission events, not restricting to those giving rise to cases within 4 years (Supplementary Material S2, Table S2).

###### 

Demographic characteristics associated with infector cases that have transmitted to another sampled or non-sampled case within 4 years. Cases collected after 2010 and extrapulmonary cases are excluded. Odds ratios are calculated through ordered logistic regression by number of secondary infections, and *P*-values by the Wald chi-squared test, adjusted for age, sex, year and lineage

                              Infector /total   \% infectors   Odds ratio (95 % CI)   *P*-value
  --------------------------- ----------------- -------------- ---------------------- -----------
  **Year**                                                                            
    1995--1998                99/337            29.4           1                      
    1999--2001                95/346            27.5           0.9 (0.6--1.2)         
    2002--2004                89/367            24.3           0.8 (0.6--1.1)         
    2005--2007                61/288            21.2           0.6 (0.4--0.9)         
    2008--2010                25/218            11.5           0.3 (0.2--0.5)         \<0.01
  **Lineage**                                                                         
    1                         48/243            19.8           0.8 (0.6--1.2)         
    2                         20/61             32.8           1.6 (0.9--2.7)         
    3                         48/185            25.9           1.4 (0.9--1.8)         
    4                         253/1067          23.7           1                      0.05
  **Age group (years**)                                                               
    \<20                      13/55             23.6           1.6 (0.7--3.2)         
    20--29                    116/411           28.2           2.1 (1.4--3.2)         
    30--39                    132/547           24.1           1.8 (1.2--2.7)         
    40--49                    69/290            23.8           1.8 (1.2--2.8)         
    50+                       39/253            15.4           1                      0.01
  **Sex**                                                                             
    Female                    206/815           25.3           1                      
    Male                      163/741           22.0           0.8 (0.7--1.1)         0.18
  **HIV status**                                                                      
    Negative                  112/469           23.9           1                      
    Positive on ART           14/78             17.9           1.0 (0.5--1.9)         
    Positive no ART           155/639           24.3           1.0 (0.7--1.3)         1.0
    **Previous TB**                                                                   
    Yes                       35/171            20.4           0.9 (0.6--1.3)         
    No                        334/1385          24.1           1                      0.43
  **TB type**                                                                         
    Smear-positive            329/1218          27.0           1                      
    Smear-negative            40/338            11.8           0.4 (0.2--0.5)         \<0.01
  **Outcome**                                                                         
    Completed                 262/1011          25.9           1                      
    Died                      67/337            19.9           0.6 (0.5--0.9)         
    Lost/transferred          40/191            20.9           0.7 (0.4--1.0)         \<0.01
  **Isoniazid Resistance**                                                            
    Resistant                 19/108            17.6           0.6 (0.4--1.0)         
    Sensitive                 347/1402          24.8           1                      0.07
  **Rifampicin resistance**                                                           
    Resistant                 2/15              13.3           0.5 (0.1--1.8)         
    Sensitive                 363/1495          24.3           1                      0.36
  **Recent residence**                                                                
    Karonga                   263/1131          23.3           1                      
    Other Malawi              59/247            23.9           1.0 (0.7--1.3)         
    Other country             20/90             22.2           0.8 (0.5--1.4)         0.78
  **Birthplace**                                                                      
    Karonga                   242/942           25.7           1                      
    Other Malawi              52/299            17.4           0.6 (0.4--0.8)         
    Other country             66/281            23.5           0.9 (0.6--1.2)         0.02

ART, antiretroviral therapy

Genomic associations with transmission {#s5-6}
--------------------------------------

We used two complementary approaches to search for genetic variants associated with transmission, convergence testing (phyC) and GWAS analysis. We considered both individual SNPs and whole-gene variation (through aggregated SNPs) to identify significant differences between variants found in transmitting versus non-transmitting strains. Non-transmitted strains were classified as singletons that were not included in any transmission cluster (*n*=409), again excluding extrapulmonary strains and cases collected after 2010. Transmitted strains were defined as strains from cases that transmitted to at least one other host within 4 years (*n*=369). SNPs identified in known antimicrobial resistance loci and *PE/PPE* genes, which were excluded in the transmission network analysis, were also considered to determine if these sites were associated with a transmissible phenotype. We also looked for convergent evolution in the presence or absence of small INDELs in the transmitter and non-transmitter groups.

The phyC analysis revealed no SNPs or whole genes that were convergently evolved in transmissible *Mtb* strains in our population. We also applied the analysis to lineage 1 and 4 strains separately (sample sizes in lineages 2 and 3 were too small to analyse) and no significant lineage-specific associations were identified. We found significant convergent evolution in a four-codon deletion in *PPE54* (*P*=0.01, [Table 4](#T4){ref-type="table"})*,* a PE/PPE gene that has been proposed to be associated with antibiotic resistance through gene--gene interactions with other resistance loci \[[@R34]\], and in host--pathogen interactions \[[@R35]\].

###### 

Genomic variants related to transmissibility identified through evolutionary convergence testing (phyC) and genome-wide association study (GWAS) mixed model approach (SNPs) and aggregated mutation mixed model (gene)

  Locus tag   Gene name     Function                         *P*-value    Identification method   SNP, gene, insertion or deletion
  ----------- ------------- -------------------------------- ------------ ----------------------- ----------------------------------
  Rv3343c     *PPE54*       *PE*/*PPE* gene                  0.01         phyC                    Δ12 bp deletion
  Rv3751      .             Probable integrase               8.8×10^−5^   GWAS                    S\* SNP (A31A)
  Rv0974c     *accD2*       Acetyl-CoA carboxylase           2.6×10^−4^   GWAS                    NS\*\* SNP (N125H)
  Rv3812      *PE_PGRS62*   *PE*/*PPE* gene                  3.1×10^−4^   GWAS                    Gene
  Rv0056      *rplI*        50S ribosomal protein L9         3.9×10^−4^   GWAS                    Δ3 bp insertion
  Rv2077c     .             Possible transmembrane protein   6.2×10^−4^   GWAS                    Δ3 bp deletion

\*, synonymous; \*\*, non-synonymous.

A GWAS analysis revealed variants that are potentially linked to transmissibility ([Table 4](#T4){ref-type="table"}). The most statistically significant variant was the synonymous SNP A31A in *Rv3751,* a non-essential gene coding for a probable phage integrase (*P*=8.8×10^−5^). We found two further loci that were found to be less significantly associated with transmissibility in our data (*P*\<10^−4^), a non-synonymous mutation N125H in *accD2* encoding an acetyl-CoA carboxylase subunit and the *PE*/*PPE* gene *Rv3812* identified through the gene-level, aggregated-mutation GWAS. In addition, we found fewer significant associations (*P*\<10^−4^) in a 3 bp deletion in Rv2077c, a possible transmembrane protein, and a 3 bp insertion in *rplI*, which codes for the 50 s ribosomal protein L9. Five genomic regions previously identified as being involved in transmission in a low-burden setting \[[@R36]\] were not validated in our study (*P*\>0.05; Supplementary Material S2, Table S3).

Discussion {#s6}
==========

Accurate reconstruction and analysis of TB transmission networks can provide insights into the factors that can influence the spread of the infection. Here we present a comprehensive large-scale study of transmission in a high-incidence region. We applied a sophisticated two-step Bayesian approach to reconstruct TB transmission networks from WGS data, allowing for within-host evolution and non-sampled hosts between sampled cases \[[@R3]\], the absence of which has been a limitation in previous studies.

The characteristics of the resulting transmission networks are consistent with a population with some latent infection, with a median generation time between transmission events of 1.7 years (IQR 0.9--3.2 years). The median distance between directly linked cases ranged from 0 to 12 SNPs, supporting a previous estimate found in this population between index patients and their identified prior contacts \[[@R8]\]. Network reconstruction has allowed us to gain further insights into the demographic factors associated with transmission in this setting and identify genomic variants that may be associated with transmissibility.

There are limitations with the methods used to infer transmission events and identify infector strains. While intermediate hosts between sampled cases were inferred, transmission from a sampled case to a non-sampled case that does not transmit onwards would not be captured and, in this scenario, the sampled case will not be characterized as an infector. Furthermore, our measure of transmission is necessarily time-limited: disease may occur up to a lifetime after infection, whereas we have taken a 4-year window, so underestimating transmission. However, the approach used in this study is a huge step towards a more complete reconstruction of transmission to reveal associated risk factors, including in cohorts with incomplete sampling, which can be used to prioritize patients and their contacts with a high possibility of onward transmission.

We found clear lineage differences in transmissibility and recent infection in our population, with lineage 2 strains exhibiting the greatest proportion of recently infected cases and the highest transmissibility, followed by lineage 3 strains. These lineages were also characterized by larger transmission clusters of cases with low genetic diversity. Increased transmission of lineage 2 strains, particularly in the Beijing subtype, has been reported in previous work in the Karonga population \[[@R6]\], as well as studies in other regions \[[@R37]\]. [@R6] In this study though, we do not see evidence that lineage 2 strains increase in frequency, with a peak frequency early in study period around 1999--2002. This may be driven by high local transmission in a small number of lineage 2 clusters with few imported cases that are persisting in the study area, in contrast to lineage 4 strains that are more dominant in the region and account for the majority of imported cases from outside Karonga \[[@R6]\], and thus will include a greater number of unlinked cases. Lineage 1 strains were found in small clusters composed of significantly more diverse strains and were the least transmissible, with the lowest proportion of recent infection. This supports evidence that lineage 1 strains, which are considered 'ancient', have lower virulence than the 'modern' lineages 2, 3 and 4 \[[@R40]\].

The decrease in transmission by calendar year reported previously up to the year 2010 \[[@R6]\] is confirmed in this new analysis and has continued from 2011 to 2014, though surprisingly it is not seen in the proportion of disease due to recent infection in the latest period. The lowest proportion of recent infection and transmission was found in those aged more than 50 years and this may reflect an increase in relapse shown previously \[[@R11]\], or the higher risk of reactivation due to a weakened immune system with age \[[@R41]\], or the lower chance of catching or spreading the infection as mobility and contact outside the home decreases.

We also looked at the underlying factors that characterize larger, persistent transmission clusters that have been circulating in the population over a long period, defined as clusters with \>10 cases transmitting at a rate of \>1 case per year. The associations with age, lineage and residence were similar to those found in other analyses \[[@R42]\]. Interestingly, HIV-positive patients were more likely to have large cluster strains, whereas the evidence of association between HIV infection and recent infection was weaker. It is possible that nosocomial transmission in HIV testing and treatment centres has contributed to these clusters \[[@R43]\]. Although it has been suggested that HIV-positive patients transmit less than HIV-negative patients, because they tend to be diagnosed earlier or die quickly, we found no evidence of reduced transmission.

Comparing the full genomic variation in strains that have been identified as transmitting to at least one recipient against cases with no evidence of onward transmission, we were able to look for possible mutations that were positively associated with transmissible strains. Two complementary methods, phyC and GWAS, were employed to test for differences between these groups, both in single-site mutations (SNPs and INDELS) and in aggregated mutation differences within whole genes. The GWAS approach revealed SNPs in *Rv3751*, *accD2*, *Rv3812*, *rplI* and Rv2077c as potentially associated with transmissibility. Members of the *accD* gene family have been linked to persistence of the *Mtb* bacterium \[[@R44]\]. The *PE/PPE* gene *Rv3812* has a role in the host immune response and virulence of the pathogen \[[@R45]\]. The phyC evolutionary convergence approach revealed a 12 bp deletion within *PPE54*, validated through manual inspection of alignment files and *de novo* assemblies of isolates, which is an important gene for *in vitro* growth and host--pathogen interactions \[[@R35]\], as well as isoniazid and rifampicin resistance \[[@R34]\].

Previous work using a *phyC* approach identified five genomic regions involved in transmission in a low-burden setting in the Netherlands. None were validated in our analysis, although we did have poor sequencing coverage in *Rv2815--2816* c and *Rv3512*, so we can not explicitly rule out a role in transmissibility within our population (Supplementary Material S2, Table S3). These differences may be explained by disease burden (low-burden vs high-burden setting), methodologies (the transmissibility phenotype in the Netherlands population was defined using a combination of clustering through DNA fingerprinting and a measure of transmission risk using demographic features) and genetic variability within the two sample populations \[[@R36]\].

In general, any loci associated with transmissibility need to be validated in other cohorts and settings, and experimentally. Our dataset contained few lineage 2 and 3 strains that did not cluster in transmission networks, limiting our ability to conduct lineage-specific association tests. The higher transmission found in these lineages may be driven by lineage-specific genomic variation that may be revealed by testing cohorts with a high proportion of lineage 2 and 3 strains, including those sourced from East Asia and the Indian subcontinent. Putative variants found to be associated with transmissibility through genomic analysis can be experimentally validated using the CRISPR/cas9 system, with methods specific to gene modification in *[Mycobacterium](http://doi.org/10.1601/nm.6310)* species beginning to be developed \[[@R46]\].

There is a body of evidence to suggest that successful transmission and virulence in *Mtb* can be affected by mutation in key resistance-conferring genes, with both higher and lower levels of transmission depending on the setting and strain resistance profiles \[[@R47]\]. In this analysis, isoniazid-resistant strains were less likely to transmit but more likely to be due to recent transmission, but there were few rifampicin-resistant strains. It is also likely that in a high-burden setting host demographic and genetic factors will play a larger role in disease susceptibility, the spread of infection and the development of disease as individuals will be exposed to higher levels of contact with potentially infectious individuals \[[@R51]\]. As such, the likelihood of transmission from host to recipient is not isolated to the pathogenic virulence and fitness but also to host--pathogen interactions, and this may go towards explaining the small number of *Mtb* genes found to be associated with transmission in our population. Incorporating host genome differences and interactions with pathogen in work of this nature would offer a more complete understanding of the underlying factors influencing the spread of *Mtb*.

Conclusions {#s7}
===========

Our work applied a sophisticated Bayesian approach to reconstruct TB transmission networks with high confidence in high-burden settings, using WGS data from a large-scale, long-term study. It has built upon a previous study detailing transmission in the region \[[@R6]\] by extending the study for a longer period and updating the methods for transmission reconstruction using recent advances. We have validated previous findings to support increased transmissibility of lineage 2 and 3 strains. In addition, we found evidence that differences in age and lineage can influence the likelihood of large, persistent transmission clusters. We identified three potential genes that may be associated with transmissible strains of *Mtb* based on significant associations with transmissibility in our population and previous studies on their function \[[@R34]\], which can be used as potential target sites for further validation studies. While this work highlights the complex nature of identifying the drivers of transmission in TB populations, the methods applied can be used as a framework for future studies, where ideally both host and pathogen genomic components should be integrated. Ultimately, any insights gained into genetic and non-genetic factors linked to transmissibility have the potential to inform much-needed disease control and management strategies to reduce the spread of TB globally.
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